Guidelines of the brazilian medical association for the treatment of social anxiety disorder;Diretrizes da associação médica brasileira para o tratamento do transtorno de ansiedade social

Revista Brasileira de Psiquiatria

Volumn 33, Issue 3, 2011, Pages 292-302

  Levitan, Michelle N ^a,d   Chagas, Marcos H N ^b,d   Crippa, José A S ^b,d   Manfro, Gisele G ^c,e   Hetem, Luiz A B ^b   Andrada, Nathalia C ^f   Salum, Giovanni A ^c,e   Isolan, Luciano ^c   Ferrari, Maria C F ^b,d   Nardi, Antonio E ^a,d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d INCT Instituto Nacional de Ciência e Tecnologia Translacional em ^*  (Brazil)

^e INCT Instituto Nacional de Psiquiatria do Desenvolvimento para a Infancia e Adolescencia ^*  (Brazil)

^f Programa Diretrizes da Associação Médica Brasileira   (Brazil)

Author keywords

Guidelines; Medication adherence; Phobic disorders; Psychotherapy; Randomized controlled trials as topic

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BRAZIL; COGNITIVE THERAPY; COMORBIDITY; DISEASE COURSE; MEDICAL SOCIETY; MEDLINE; PRACTICE GUIDELINE; SOCIAL PHOBIA; STRUCTURED QUESTIONNAIRE;

ADOLESCENT; ADULT; ANXIETY DISORDERS; BRAZIL; CHILD; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; HUMANS; PHOBIC DISORDERS; PRACTICE GUIDELINES AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 82555189257     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462011000300014     Document Type: Article

References (79)

1. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):629-40.
2. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry. 1991;48(10):938-45.
3. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004;61(10):1005-1013.
4. Fava GA, Grandi S, Rafanelli C, Ruini C, Conti S, Belluardo P. Long-term outcome of social phobia treated by exposure. Psychol Med. 2001;31(5):899-905.
5. Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, Campeas R, Liebowitz MR. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010;67(3):286-95.
6. Huppert JD, Roth DA, Foa EB. Cognitive-behavioral treatment of social phobia: new advances. Curr Psychiatry Rep. 2003; 5 (4):289-96.
7. Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, Waddington L, Wild J. Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial. J Consult Clin Psychol. 2006;74 (3):568-78.
8. Rapee RM, Heimberg RG. A cognitive-behavioral model of anxiety in social phobia. Behav Res Ther. 1997;35(8):741-56.
9. Eskildsen A, Hougaard E, Rosenberg NK. Pre-treatment patient variables as predictors of drop-out and treatment outcome in cognitive behavioural therapy for social phobia: A systematic review. Nord J Psychiatry. 2010;64(2):94-105.
10. Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM. Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther. 2003;41(9):991-1007.
11. Scholing A, Emmelkamp PM. Exposure with and without cognitive therapy for generalized social phobia: effects of individual and group treatment. Behav Res Ther. 1993;31(7):667-81.
12. Wlazlo Z, Schroeder-Hartwig K, Hand I, Kaiser G, Munchau N. Exposure in vivo vs social skills training for social phobia: long-term outcome and differential effects. Behav Res Ther. 1990;28(3):181-93.
13. Mattick RP, Peters L. Treatment of severe social phobia: effects of guided exposure with and without cognitive restructuring. J Consult Clin Psychol. 1988;56(2):251-60.
14. Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry. 1998;55 (12): 1133-141.
15. Silverman WK, Pina AA, Viswesvaran C. Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. J Clin Child Adolesc Psychol. 2008; 37(1):105-30.
16. Segool NK, Carlson JS. Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety. 2008;25(7):620-31.
17. Albano AM, Marten PA, Holt CS, Heimberg RG, Barlow DH. Cognitivebehavioral group treatment for social phobia in adolescents.A preliminary study. J Nerv Ment Dis. 1995;183 (10):649-656.
18. Spence SH, Donovan C, Brechman-Toussaint M. The treatment of childhood social phobia: the effectiveness of a social skills training-based, cognitive-behavioural intervention, with and without parental involvement. J Child Psychol Psychiatry. 2000;41(6):713-26.
19. Gallagher HM, Rabian BA, McCloskey MS. A brief group cognitivebehavioral intervention for social phobia in childhood. J Anxiety Disord. 2004;18(4):459-79.
20. Silverman WK, Kurtines WM, Ginsburg GS, Weems CF, Rabian B, Serafini LT. Contingency management, self-control, and education support in the treatment of childhood phobic disorders: a randomized clinical trial. J Consult Clin Psychol. 1999;67(5):675-87.
21. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother. 2008;8(2):235-57.
22. RB. The role of drug therapy in social phobia. J Affect Disord. 1998;50 Suppl 1:S35-39.
23. Simpson HB, Schneier FR, Campeas RB, Marshall RD, Fallon BA, Davies S, Klein DF, Liebowitz MR. Imipramine in the treatment of social phobia. J Clin Psychopharmacol. 1998;18 (2):132-35.
24. Versiani M, Mundim FD, Nardi AE, Liebowitz MR. Tranylcypromine in social phobia. J Clin Psychopharmacol. 1988;8(4):279-83.
25. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, Flower T, Davenport C, Louis B. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003;71(6):1058-1067.
26. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002;22(3):257-62.
27. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, Jacobsson E, Flyckt K, Grohp M, Bergstrom M, Pich EM, Nilsson LG, Bani M, Langstrom B, Fredrikson M. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry. 2005;58(2):132-42.
28. Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(7):785-92.
29. Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S, Pecknold JC, Hadrava V, Swinson RP. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158 (2):275-81.
30. Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004;19 (4):241-48.
31. Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005;186:222-26.
32. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebocontrolled study. Paroxetine Study Group. Br J Psychiatry. 1999;175:120-26.
33. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280 (8):708-13.
34. Stein DJ, Berk M, Els C, Emsley RA, Gittelson L, Wilson D, Oakes R, Hunter B. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J. 1999;89(4):402-6.
35. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebocontrolled study. Acta Psychiatr Scand. 1999;100 (3):193-8.
36. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebocontrolled study. Am J Psychiatry. 1999;156 (5):756-60.
37. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl). 1994;115(1-2):128-34.
38. Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebocontrolled study. Int J Neuropsychopharmacol. 2007;10 (2):263-74.
39. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005;177 (3):280-88.
40. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24(5):488-96.
41. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005;66 (2):238-47.
42. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004;19(6):387-96.
43. Schneier FR, Blanco C, Campeas R, Lewis-Fernandez R, Lin SH, Marshall R, Schmidt AB, Sanchez-Lacay JA, Simpson HB, Liebowitz MR. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress Anxiety. 2003;17(4):191-96.
44. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161:353-60.
45. Blanco C, Schneier FR, Schmidt A, Blanco-Jerez CR, Marshall RD, Sanchez-Lacay A, Liebowitz MR. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18(1):29-40.
46. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13(6):423-28.
47. Versiani M, Nardi A, Figuera I, Marques C. Double-blind placebo controlled trial with bromazepam in social phobia. J Bras Psiquiatr. 1997;46:167-71.
48. James I, Savage I. Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo. Am Heart J.1984;108(4 Pt 2):1150-1155.
49. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61(11):1153-1162.
50. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003; 42 (4):415-23.
51. Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry. 2001;40(5):564-71.
52. Isolan L, Pheula G, Salum GA Jr, Oswald S, Rohde LA, Manfro GG. An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol. 2007;17(6): 751-60.
53. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005;66(10):1270-1278.
54. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry. 2002;59(12):1111-1118.
55. Brown EJ, Heimberg RG, Juster HR. Social phobia subtype and avoidant personality disorder: Effect on severity of social phobia, impairment, and outcome of cognitive behavioral treatment. Behav Ther. 1995;26:467-86.
56. Turner SM, Beidel DC, Wolff PL, Spaulding S, Jacob RG. Clinical features affecting treatment outcome in social phobia. Behav Res Ther. 1996;34(10): 795-804.
57. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158 (10):1725-1727.
58. JR. Pharmacotherapy of social phobia. Acta Psychiatr Scand Suppl. 2003; (417):65-71.
59. Menezes GB, Fontenelle LF, Versiani M. Early-onset social anxiety disorder in adults: clinical and therapeutic features. Rev Bras Psiquiatr. 2005;27(1):32-6.
60. Black B, Uhde TW. Psychiatric characteristics of children with selective mutism: a pilot study. J Am Acad Child Adolesc Psychiatry. 1995;34(7):847-56.
61. Bergman RL, Piacentini J, McCracken JT. Prevalence and description of selective mutism in a school-based sample. J Am Acad Child Adolesc Psychiatry. 2002;41(8):938-46.
62. Steinhausen HC, Juzi C. Elective mutism: an analysis of 100 cases. J Am Acad Child Adolesc Psychiatry. 1996;35(5):606-14.
63. Ford MA, Sladeczek IE, Carlson J, Kratochwill TR. Selective mutism: Phenomenological characteristics. Sch Psychol. 1998;13(3):192-27.
64. Kumpulainen K, Rasanen E, Raaska H, Somppi V. Selective mutism among second-graders in elementary school. Eur Child Adolesc Psychiatry. 1998;7(1):24-29.
65. Dummit ES, 3rd, Klein RG, Tancer NK, Asche B, Martin J. Fluoxetine treatment of children with selective mutism: an open trial. J Am Acad Child Adolesc Psychiatry. 1996;35(5):615-21.
66. Manassis K, Tannock R. Comparing interventions for selective mutism: a pilot study. Can J Psychiatry. 2008;53(10):700-3.
67. Sharkey L, Mc Nicholas F, Barry E, Begley M, Ahern S. Group therapy for selective mutism - a parents' and children's treatment group. J Behav Ther Exp Psychiatry. 2008;39(4):538-45.
68. Ledley DR, Huppert JD, Foa EB, Davidson JR, Keefe FJ, Potts NL. Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depress Anxiety. 2005;22(4):161-67.
69. Marom S, Gilboa-Schechtman E, Aderka IM, Weizman A, Hermesh H. Impact of depression on treatment effectiveness and gains maintenance in social phobia: a naturalistic study of cognitive behavior group therapy. Depress Anxiety. 2009;26(3):289-300.
70. Erwin BA, Heimberg RG, Juster H, Mindlin M. Comorbid anxiety and mood disorders among persons with social anxiety disorder. Behav Res Ther. 2002;40(1):19-35.
71. Smits JA, Minhajuddin A, Jarrett RB. Cognitive therapy for depressed adults with comorbid social phobia. J Affect Disord. 2009;114(1-3): 271-78.
72. Buckner JD, Schmidt NB. Understanding social anxiety as a risk for alcohol use disorders: fear of scrutiny, not social interaction fears, prospectively predicts alcohol use disorders. J Psychiatr Res. 2009;43(4):477-83.
73. Robinson J, Sareen J, Cox BJ, Bolton J. Self-medication of anxiety disorders with alcohol and drugs: Results from a nationally representative sample. J Anxiety Disord. 2009;23(1):38-45.
74. Buckner JD, Timpano KR, Zvolensky MJ, Sachs-Ericsson N, Schmidt NB. Implications of comorbid alcohol dependence among individuals with social anxiety disorder. Depress Anxiety. 2008;25(12):1028-1037.
75. Mennin DS, Heimberg RG, Jack MS. Comorbid generalized anxiety disorder in primary social phobia: symptom severity, functional impairment, and treatment response. J Anxiety Disord. 2000;14(4):325-43.
76. Kendall PC, Brady EU, Verduin TL. Comorbidity in childhood anxiety disorders and treatment outcome. J Am Acad Child Adolesc Psychiatry. 2001;40(7):787-94.
77. Nardi AE, Lopes FL, Valenca AM, Freire RC, Nascimento I, Veras AB, Mezzasalma MA, de-Melo-Neto VL, Soares-Filho GL, King AL, Grivet LO, Rassi A, Versiani M. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res. 2010;175(3):260-65.
78. Chagas MH, Nardi AE, Manfro GG, Hetem LA, Andrada NC, Levitan MN, Salum GA, Isolan L, Ferrari MC, Crippa JA. [Guidelines of the Brazilian Medical Association for the diagnosis and differential diagnosis of social anxiety disorder]. Rev Bras Psiquiatr. 2010;32(4):444-52.
79. Canadian Psychiatric Association. Clinical practice guidelines.Management of anxiety disorders. Can J Psychiatry. 2006; 51(8 Suppl. 2):9S-91S.